» Articles » PMID: 35386502

Impact of Mode of Conception on Early Pregnancy Human Chorionic Gonadotropin Rise and Birth Weight

Overview
Journal F S Rep
Date 2022 Apr 7
PMID 35386502
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess whether the mode of conception and embryo biopsy impact first-trimester human chorionic gonadotropin (hCG) dynamics and subsequent risk of small for gestational age (SGA) or large for gestational age (LGA).

Design: Retrospective cohort study.

Setting: University fertility center.

Patients: Six hundred-two pregnant patients with singleton live births.

Interventions: Serial serum hCG measurements were obtained between 10 and 28 days postconception to determine the within-woman rate of change in hCG (slope) by mode of conception (unassisted pregnancy, fresh embryo transfer (ET), frozen ET, and frozen ET following preimplantation genetic testing for aneuploidy (PGT-A).

Main Outcome Measures: Primary outcomes included birth weight, SGA, and LGA.

Results: Mode of conception is not independently associated with birth weight, SGA, or LGA. Mediation analysis revealed an expected one-day increase in log-transformed hCG varied by mode of conception: unassisted (0.41), fresh ET (0.39), frozen ET (0.42), PGT-A (0.44). Human chorionic gonadotropin rise has a positive effect on birth weight (55 g per SD increase in hCG slope) and is associated with SGA (odds ratio, 0.65), but not with LGA (odds ratio, 1.18).

Conclusions: Human chorionic gonadotropin rise is an important mediator of the mode of conception/birth weight relationship. Preimplantation genetic testing for aneuploidy has the highest rate of hCG rise, followed by frozen ET, unassisted, and fresh ET. Faster rise is associated with higher birth weight and lower risk of SGA but does not impact LGA risk. Importantly, PGT-A does not increase the risk of extreme birth weight relative to other modes of conception evaluated.

Citing Articles

Birthweight after assisted reproductive technology: clinical decision-making and patient counseling.

Burks H F S Rep. 2022; 3(1):8-9.

PMID: 35386507 PMC: 8978074. DOI: 10.1016/j.xfre.2022.02.003.

References
1.
Adamson G, de Mouzon J, Chambers G, Zegers-Hochschild F, Mansour R, Ishihara O . International Committee for Monitoring Assisted Reproductive Technology: world report on assisted reproductive technology, 2011. Fertil Steril. 2018; 110(6):1067-1080. DOI: 10.1016/j.fertnstert.2018.06.039. View

2.
Sato T, Sugiura-Ogasawara M, Ozawa F, Yamamoto T, Kato T, Kurahashi H . Preimplantation genetic testing for aneuploidy: a comparison of live birth rates in patients with recurrent pregnancy loss due to embryonic aneuploidy or recurrent implantation failure. Hum Reprod. 2019; 34(12):2340-2348. DOI: 10.1093/humrep/dez229. View

3.
Zhang W, von Versen-Hoynck F, Kapphahn K, Fleischmann R, Zhao Q, Baker V . Maternal and neonatal outcomes associated with trophectoderm biopsy. Fertil Steril. 2019; 112(2):283-290.e2. PMC: 6527329. DOI: 10.1016/j.fertnstert.2019.03.033. View

4.
Berntsen S, Soderstrom-Anttila V, Wennerholm U, Laivuori H, Loft A, Oldereid N . The health of children conceived by ART: 'the chicken or the egg?'. Hum Reprod Update. 2019; 25(2):137-158. DOI: 10.1093/humupd/dmz001. View

5.
Vitez S, Forman E, Williams Z . Preimplantation genetic diagnosis in early pregnancy loss. Semin Perinatol. 2019; 43(2):116-120. DOI: 10.1053/j.semperi.2018.12.009. View